What is the recommended dosage and usage of Dabigatran (Pradaxa) for patients with non-valvular atrial fibrillation and deep vein thrombosis?

Dabigatran Dosing and Usage

Non-Valvular Atrial Fibrillation

For stroke prevention in non-valvular atrial fibrillation, use dabigatran 150 mg twice daily in patients with creatinine clearance >30 mL/min, as this dose demonstrated superior efficacy compared to warfarin with a 34% reduction in stroke/systemic embolism and 74% reduction in hemorrhagic stroke. 1, 2, 3

Standard Dosing Algorithm by Renal Function

• CrCl >30 mL/min: 150 mg orally twice daily 1, 4
• CrCl 15-30 mL/min: 75 mg twice daily (though this dose was never tested in the RE-LY trial and may provide inadequate anticoagulation based on pharmacokinetic data) 1, 3, 4
• CrCl <15 mL/min or dialysis: No dosing recommendations can be provided—avoid use 1, 4

Critical Drug Interaction Adjustments

Reduce dabigatran to 75 mg twice daily when coadministering dronedarone or systemic ketoconazole in patients with CrCl 30-50 mL/min, as these P-glycoprotein inhibitors produce dabigatran exposure equivalent to severe renal impairment 1, 3, 4

• Avoid dabigatran entirely with P-glycoprotein inhibitors (dronedarone, ketoconazole) if CrCl <30 mL/min 1, 4
• Exercise caution with other P-gp inhibitors (verapamil, amiodarone, quinidine) which may increase dabigatran levels 2

Mandatory Renal Function Monitoring

Calculate creatinine clearance using the Cockcroft-Gault formula before initiating therapy and reassess at least annually, or more frequently when clinical deterioration occurs (acute illness, dehydration, new medications) 1, 3, 4

• Discontinue dabigatran if acute renal failure develops and consider alternative anticoagulation 4

Key Clinical Considerations for AF

• Age alone does not mandate dose reduction—dosing is based solely on renal function, not chronological age 3
• The 150 mg twice daily dose provides superior stroke prevention compared to the 110 mg dose (which is not FDA-approved in the United States for AF) 1
• Dabigatran 150 mg twice daily shows similar major bleeding rates to warfarin but 50% higher gastrointestinal bleeding risk 3
• Dyspepsia occurs in 11-12% of patients 3
• Contraindications: prosthetic heart valves, hemodynamically significant valve disease, severe renal failure (CrCl <15 mL/min), advanced liver disease with impaired baseline clotting function 1, 2

---

Deep Vein Thrombosis Treatment

For DVT treatment, administer dabigatran 150 mg twice daily after 5-10 days of parenteral anticoagulation in patients with CrCl >30 mL/min. 4

DVT Treatment Protocol

• Initial therapy: Parenteral anticoagulation (LMWH, UFH, or fondaparinux) for 5-10 days 4
• Transition to dabigatran: 150 mg orally twice daily 4
• Renal requirement: CrCl must be >30 mL/min 4
• Contraindication: No dosing recommendations exist for CrCl ≤30 mL/min or dialysis patients—avoid use 4

DVT Recurrence Prevention

For secondary prevention of recurrent DVT/PE, continue dabigatran 150 mg twice daily after completing initial treatment in patients with CrCl >30 mL/min. 4

• Duration of therapy should be based on individual thrombotic risk factors and bleeding risk
• Same renal function requirements apply (CrCl >30 mL/min) 4

Drug Interactions for VTE Indications

Avoid coadministration of dabigatran with P-glycoprotein inhibitors in patients with CrCl <50 mL/min when treating DVT/PE, as the safety margin is narrower than in AF indications 4

---

Critical Safety Warnings

Bleeding Risk Management

• Major bleeding rates with dabigatran 150 mg are similar to warfarin, but hemorrhagic stroke risk is 74% lower 1, 3
• Gastrointestinal bleeding is 50% higher than warfarin 1, 3
• Monitor closely for bleeding signs, particularly in elderly patients and those with moderate renal impairment 1
• Idarucizumab is available as a specific reversal agent 3

Spinal/Epidural Hematoma Risk

Avoid neuraxial anesthesia or spinal puncture when possible in patients on dabigatran due to risk of spinal/epidural hematoma causing permanent paralysis. 4

• If neuraxial procedures are necessary, carefully weigh risks versus benefits 4
• Monitor frequently for neurological impairment post-procedure 4
• Risk factors include: indwelling epidural catheters, concomitant NSAIDs/antiplatelet agents, history of spinal trauma/surgery 4

Transition from Warfarin

Postmarketing surveillance identified fatal bleeding events during warfarin-to-dabigatran transitions, emphasizing the need for careful monitoring during this period 1

• Discontinue warfarin and start dabigatran when INR <2.0 1

---

Administration Details

• Twice-daily dosing is mandatory due to the 12-17 hour half-life 3, 5
• Twice-daily regimen minimizes peak-trough fluctuations (less than 2-fold variation) compared to once-daily dosing (5-fold variation) 5
• No routine INR monitoring required, though aPTT or ECT can assess anticoagulant activity if needed 3, 4
• Do not substitute different dabigatran dosage forms on a milligram-to-milligram basis 4
• Capsules must be swallowed whole—do not open, crush, or chew 4